NASDAQ:DARE

Daré Bioscience Stock News

Healthcare > Biotechnology

Buy DARE

*Your capital is at risk

$2.05

-0.0900 (-4.21%)

At Close: Jun 03, 2026

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

08:00am, Monday, 14'th Jul 2025

Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive Interim Phase 3 Results Support Ovaprene's Differentiation as a Firs

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

08:00am, Friday, 11'th Jul 2025

Exploring Strategic Partnerships to Expand Platform Beyond Reproductive Health Exploring Strategic Partnerships to Expand Platform Beyond Reproductive Health

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

05:00pm, Thursday, 12'th Jun 2025

SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, toda

Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript

11:13pm, Tuesday, 13'th May 2025

Daré Bioscience, Inc. (NASDAQ:DARE ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - President

Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

06:10pm, Tuesday, 13'th May 2025

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.84 per share a year ago.

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

04:01pm, Tuesday, 13'th May 2025

In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal probiotics in 2025 and its proprietary m

Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript

10:14pm, Monday, 31'st Mar 2025

Daré Bioscience, Inc. (NASDAQ:DARE ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - Preside

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

06:16pm, Monday, 31'st Mar 2025

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.72 per share a year ago.

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

04:01pm, Monday, 31'st Mar 2025

With increasing demand for needed treatments designed for women, Daré is taking action to make its proprietary Sildenafil Cream formulation available via prescription this year With increasing demand

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

08:00am, Monday, 24'th Mar 2025

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and well-being of women, will host a conference call and live webcast at 4

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

08:00am, Thursday, 06'th Feb 2025

DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by